The global melanoma cancer market is anticipated to grow at a CAGR of around 12.3% during the forecast period (2021-2027). The factor propelling the growth of the market include the rise in the number of FDA approvals for melanoma cancer drugs/systems produced by key market players. For instance, in July 2021, Genentech, a subsidiary of F. Hoffmann-La Roche Ltd, got the approval for Tecentriq (atezolizumab) plus Cotellic (cobimetinib) and Zelboraf (vemurafenib). These drugs are used for the treatment of BRAF V600 mutation-positive advanced melanoma. The FDA approval is supported by results from the Phase 3 IMspire150 clinical trial done on peoples who suffered from advanced melanoma and previously untreated BRAF V600 mutation. The approval will support Roche to build a strong market for the Tecentriq/Cotellic combo.
To Request a Sample of our Report on Melanoma Cancer Market: https://www.omrglobal.com/request-sample/melanoma-cancer-market
Moreover, in May 2020, SciBase, announced that it has received approval from the FDA for Nevisense 3.0, the third generation of their Nevisense system for early melanoma detection. Nevisence is an AI-based point-of-care system that is used for the non-invasive evaluation of irregular moles. Through this approval for the system to detect early melanoma cancer will support the company to expand its marketing and sales activities in the market. Thus, these approvals by FDA will impact positively the growth of the melanoma cancer market during the forecast period.
(Get 15% Discount on Buying this Report)
A full Report of Melanoma Cancer Market is Available at: https://www.omrglobal.com/industry-reports/melanoma-cancer-market
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
Segment Covered-
- By Diagnosis
- By Therapy
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape- Bristol-Myers Squibb Co., GlaxoSmithKline plc, AstraZeneca PLC, Amgen Inc, Novartis AG, Abbott Laboratories, Johnson & Johnson Services, Inc., and others.
Global Melanoma Cancer Market Segmentation
By Diagnosis
- Biopsy
- Computed Tomography (CAT) Scan
- Magnetic Resonance Imaging (MRI)
- Positron Emission Tomography (PET) Scan
By Therapy
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Radiation Therapy
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
